Novartis is paying China’s Abogen Biosciences $575 million (€512 million) upfront for global rights to ABO2203, an ...
Every Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us ...
Novo Nordisk becomes the latest major pharma player to trust the future of its drug discovery to AI. However, the Danish pharma heavyweight is going one step further: The partnership with Open AI is ...
Swedish biotech Atrogi says its oral drug ATR-258 increased lower-extremity muscle power by about 13% after eight weeks in a ...
GSK has selected a liver disease drug candidate from its collaboration with Wave Life Sciences for further development, ...
Industry leaders at Advanced Therapies Europe 2026 warned that Europe must tackle barriers across commercialisation, ...
Boehringer Ingelheim’s survodutide delivered average weight loss of up to 13.1% in a Phase 3 trial involving people with ...
In proceedings before the European Patent Office (EPO), applicants are required to „adapt“ the description to the claims of a ...
Swedish biotech AnaCardio has raised €62.5 million to take its oral heart failure drug AC01 through Phase 2b, testing whether ...
Qure’s shares fell about 40% in early trading on September 29 after its Huntington’s gene therapy missed statistical ...
Newron Pharmaceuticals will expand its Phase 3 evenamide trial outside the U.S. after the FDA decided to maintain a hold on ...
The 2025 AseBio Report shows a Spanish biotech ecosystem that is not only expanding, but attracting capital at a new scale: ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results